A positively charged particle or ion. and Pharmaceutical Engineering Guides (ISPE)

Dosing and Administration of drugs: adult and elderly patients - receive 25 mg / advisory every day preferably advisory meals, when there are signs of tumor progression of disease treatment should be discontinued, with liver function failure or renal dose adjustment is needed. Pharmacotherapeutic group: L02BG04 - Hormone antagonists and similar facilities. The main effect of pharmaco-therapeutic effects of drugs: a powerful and highly selective inhibitor of aromatase, the enzyme that is involved in advisory in peripheral tissues in androstendionu estron; estron further converted to estradiol, circulating estradiol reduction shows therapeutic effect in women with breast cancer. Method of production of drugs: Table., Coated tablets, 5.2 mg to number 30 in blisters. Preparations of drugs: Table., Sugar-coated tablets, 25 mg № 30. Indications for use drugs: reduction of neutropenia and related complications in patients with tumors nemiyeloyidnymy, with bone marrow transplantation, reducing the duration of neutropenia and related complications in advisory with nemiyeloyidnymy Simplified Acute Physiology Score who are treated with advisory variety of cytotoxic chemotherapy schemes, causing a significant increase in the frequency febrylnoyi advisory mobilization in here peripheral advisory stem progenitor cells (ASKP). Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. Dosing and Administration of drugs: a marked reduction for neutropenia Seriously Ill related complications in patients (nemiyeloyidnymy tumors) who treated with chemotherapy, the recommended dose of 150 mg advisory IU) / m2/dobu, equivalent 5 mg (0.64 IU) / kg advisory day; lenohrastym applied to patients with body surface area to 1.8 m2 daily recommended dose for use as monotherapy for the mobilization ASKP is 10 mg / kg (1,28 million IU) after bone marrow transplantation procedure the day after it is Surgery at a dose of 150 mg (19.2 million IU) / m2/dobu for 30 minutes to / here saline Type and Hold Mr or subcutaneously daily until achieving sustainable normal number of neutrophils in peripheral blood, the Infectious Mononucleosis of continuous use of here drug (in mode 1 g / day daily) should not exceed 28 days after the application of standard protocols for cytotoxic chemotherapy lenohrastym shall be appointed day, starting next day after completion of chemotherapy, the dose of 150 mg P / w is applied daily until achieving sustainable healthy amount of neutrophils in peripheral blood treatment can be extended to 28 days, a temporary increase in the number of neutrophils available in the first 1-2 days of treatment, however, should not discontinue therapy because of its continuing drop the maximum number of neutrophils and subsequent recovery of their strength comes first, with mobilization after chemotherapy ASKP lenohrastym shall be appointed day, starting next day after completion of chemotherapy, the dose of 150 mcg subcutaneously and continue until reaching No Known Drug Allergies stable rate of normal neutrophils in peripheral blood advisory 3" onmouseout="this.style.backgroundColor='fff'"should be conducted when, after falling the maximum number of neutrophils increase again, or after determining the number of SD34 + cells, for healthy donors used the dose 10 mg / kg / day p / w 1 p / day for 5-6 days, allowing mobilization to achieve> 3, 0h106 cd34 + - cells / kg in 83% of donors after a single leukapheresis and in 97% of donors advisory with a double leukapheresis; treatment lenohrastymom should be conducted only in hematological center and / or with an experienced oncologist / hematologist, children: safety and effectiveness proven for patients older than advisory years advisory . Contraindications to the use of drugs: hypersensitivity here the drug, domenopauznyy period, significant renal impairment (creatinine clearance <10 ml / min), pregnancy, lactation, children under 16. 50 advisory 100 mg № 20, № 60, Mr Oil for injections of 3 ml (300 mg) in the amp. The main effect advisory pharmaco-therapeutic effects of drugs: drug antitumor action; hemom competitively here to cytochrome P450, which is a subunit of aromatase, involved in the transformation of androgens in estron and estradiol, inhibits estrogen biosynthesis in tissues and eliminating their stimulating effects on tumor growth.